June 2025 in “Clinical Cosmetic and Investigational Dermatology” There's an urgent need for better treatments for hair loss caused by radiation therapy.
December 2025 in “Frontiers in Medicine” Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.
January 2024 in “Archives of Endocrinology and Metabolism” A new gene mutation causes insulin resistance in a girl and her mother.
1 citations
,
August 2022 in “JAAD case reports” Tofacitinib and oral minoxidil may help treat Sisaipho alopecia areata.
Blocking the Mitochondrial Pyruvate Carrier causes stress in hair follicles, which can be reduced by an ISR inhibitor.
4 citations
,
January 2020 in “PubMed” JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Upadacitinib effectively treats severe alopecia areata and is safe.
RXR and RAR proteins in skin may help with cell growth, hair growth, and gland function.
1 citations
,
April 2013 in “Journal of Investigative Dermatology”
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
April 2025 in “Dermatology Practical & Conceptual” Alopecia areata patients have higher systemic inflammation, even in mild cases.
1 citations
,
April 2023 in “Portuguese Journal of Dermatology and Venereology” JAK inhibitors are effective treatments for alopecia areata.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib was effective in treating both early and late onset alopecia areata.
1 citations
,
January 2023 in “Cutis” The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
September 2004 in “Hair transplant forum international” The ABHRS has outlined its goals for the next year.
January 2026 in “Frontiers in Public Health” Baricitinib and tofacitinib have different safety patterns in treating alopecia areata.
9 citations
,
January 2013 in “Indian journal of dermatology, venereology, and leprology” Infliximab may cause hair loss in Crohn's disease patients.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in teens with severe alopecia areata.
35 citations
,
January 2002 in “Dermatology” A woman's hair loss during treatment with specific hepatitis C drugs grew back after stopping the medication.
July 2025 in “The Journal of Dermatology” Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.
February 2025 in “PubMed” CS12192 effectively treats alopecia areata with better safety than current options.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
January 2014 in “IRL - University of Missouri, St. Louis (University of Missouri–St. Louis)” Auxin pathways help maintain balance in plant growth and development.
June 2023 in “British Journal of Dermatology” Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
November 2025 in “Scientific Reports” AI improves accuracy and consistency in diagnosing male pattern hair loss.
Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.
January 2025 in “Balkan Medical Journal” Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.
August 2021 in “Revista Colombiana de Reumatología/Revista Colombiana de Reumatologia” Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.
4 citations
,
December 2014 in “Dermatologica sinica/Zhōnghuá pífūkē yīxué zázhì” The excimer lamp is a safe and effective treatment for severe alopecia areata.